Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc., adding one potential blockbuster in lung cancer and another already on-the-market therapy.
Category: ARIAD Pharmaceuticals
Why Ariad Pharmaceuticals, VCA, and Exact Sciences Jumped Today
The stock market started the new week on a sluggish note Monday, and the broadest-based market benchmarks gave up ground as the Dow fell further away from the 20,000 mark. Even though the Nasdaq Composite climbed to new highs, a $2 per barrel plunge in the price of oil to fall below $53 weighed on sentiment.